...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes care >Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: A prospective, randomized, placebo-controlled study
【24h】

Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: A prospective, randomized, placebo-controlled study

机译：肌肉肌醇在孕妇中的妊娠期糖尿病的补充和发作，具有2型糖尿病的家族史：一项潜在，随机，安慰剂对照研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE-To check the hypothesis that myo-inositol supplementation may reduce gestational diabetesmellitus (GDM) onset in pregnant women with a family history of type 2 diabetes. RESEARCH DESIGN AND METHODS-A 2-year, prospective, randomized, open-label, placebo-controlled study was carried out in pregnant outpatients with a parent with type 2 diabetes who were treated fromthe end of the first trimester with 2 g myo-inositol plus 200 ??g folic acid twice a day (n = 110) and in the placebo group (n = 110), who were only treated with 200 mg folic acid twice a day. The main outcome measure was the incidence of GDM in both groups. Secondary outcome measures were as follows: the incidence of fetal macrosomia (>4,000 g), gestational hypertension, preterm delivery, caesarean section, shoulder dystocia, neonatal hypoglycemia, and neonatal distress respiratory syndrome. GDM diagnosis was performed according to the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations. RESULTS-Incidence of GDM was significantly reduced in the myo-inositol group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04). In the myo-inositol group, a reduction of GDM risk occurrence was highlighted (odds ratio 0.35). A statistically significant reduction of fetal macrosomia in the myo-inositol group was also highlighted together with a significant reduction in mean fetal weight at delivery. In the other secondary outcome measures, there were no differences between groups. CONCLUSIONS-myo- Inositol supplementation in pregnant women with a family history of type 2 diabetes may reduce GDM incidence and the delivery of macrosomia fetuses. ? 2013 by the American Diabetes Association.
机译：目的 - 检查肌肌醇补充剂可降低孕妇患有2型糖尿病的孕妇的妊娠糖尿病（GDM）发病的假设。研究设计和方法 - 在怀孕门诊患者中，用患有2型糖尿病的患者进行了2年，前瞻性，随机，开放标签，安慰剂对照研究，患有2磅肌醇的末期治疗加200 ?? G叶酸两次（n = 110）和安慰剂组（n = 110），每天仅用200mg叶酸治疗两次。主要结果测量是两组GDM的发生率。次要结果措施如下：胎儿麦克风（> 4,000g）的发生率，妊娠高血压，早产，剖腹产段，肩腹部，新生儿低血糖症和新生儿窘迫呼吸综合征。根据糖尿病和怀孕研究组（IADPSG）建议的国际协会进行GDM诊断。与安慰剂组相比，Myo-intositol组中GDM的结果显着降低了GDM：6 vs.15.3％（P = 0.04）。在肌肌醇组中，突出了GDM风险发生的减少（赔率比0.35）。肌肉肌醇组中胎儿麦科瘤的统计学显着降低也突出显示，在递送时平均胎儿重量显着降低。在其他次要结果措施中，群体之间没有差异。结论 - 患有2型糖尿病家族史的孕妇的肌醇补充可能会降低GDM发病率和越野胎儿的递送。还是2013年由美国糖尿病协会。

著录项

  • 来源
    《Diabetes care》 |2013年第4期|共4页
  • 作者

    DAnnaR.; ScilipotiA.; GiordanoD.; CarusoC.; CannataM.L.; InterdonatoM.L.; CorradoF.; DiBenedettoA.;

  • 作者单位

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Gynecological and Obstetrical Sciences University of Messina Messina Italy;

    Department of Internal Medicine University of Messina Messina Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号